Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?

Molebogeng X. Rangaka, Yohhei Hamada, Ibrahim Abubakar

Research output: Contribution to journalComment/debate

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)529-531
Number of pages3
JournalThe Lancet Respiratory Medicine
Issue number6
Publication statusPublished - Jun 2022
Externally publishedYes

Bibliographical note

Funding Information:
MXR is the recipient of a Wellcome Trust Investigator Award on tuberculosis and diabetes. IA is the recipient of an EU funded award to End-VOC (End SARS-CoV-2 variants of concern). The authors declare no other competing interests.

Cite this